Allogeneic Anti-CD38 DAR-T Cells STI-1492

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of human allogeneic T-lymphocytes that are gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt the expression of endogenous T-cell receptor (TCR) alpha and to express a dimeric antigen receptor (DAR) composed of a fragment antigen-binding variable region (Fab) recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, allogeneic anti-CD38 DAR-T cells STI-1492 are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. The disruption of endogenous TCR alpha prevents graft-versus-host disease (GvHD).

**Synonyms:** - Allogeneic Anti-CD38 A2 KOKI DAR T-cells STI-1492 - Allogeneic Anti-CD38 Dimeric Antigen Receptor-expressing T-lymphocytes STI-1492 - Allogeneic Second Generation Anti-CD38 Knock-out Knock-in Dimeric Antigen Receptor-4-1BB-CD3zeta-expressing T-cells STI-1492 - Anti-CD38 A2 KOKI DAR Allogeneic T Cells STI-1492 - STI 1492 - STI-1492 - STI1492